PT  - JOURNAL ARTICLE
AU  - Hossain, Mohammad D.
AU  - Siddik, Abu Bakar
AU  - Pinky, Susmita Dey
AU  - Sauda, Tonazzina Hossain
AU  - Nasreen, Fahtiha
AU  - Sarker, Pallab
AU  - Rahman, Masum
TI  - Central diabetes insipidus induced by temozolomide: A literature Review
AID  - 10.1101/2021.02.18.21252028
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.18.21252028
4099  - http://medrxiv.org/content/early/2021/02/21/2021.02.18.21252028.short
4100  - http://medrxiv.org/content/early/2021/02/21/2021.02.18.21252028.full
AB  - Temozolomide has been the most used chemotherapeutic drug for glioblastoma and various CNS malignancies. Although myelosuppression has the most severe adverse effect, central diabetes insipidus (CDI) has been found as an infrequent side effect. CDI is characterized by decreased antidiuretic hormone secretion from posterior pituitary, thereby the inability to concentrate the urine with variable degrees of polyuria and compensatory polydipsia. Following a comprehensive literature search of several databases from 1990 to October 2020, which were limited to the English language, patient data were analyzed to demonstrate the risk factors, severity, reversibility of the disease, and overall survival. Total nine cases found who developed CDI following TMZ treatment. All patients manifest hyperosmolar symptoms like polyuria and polydipsia within 3 to 12 weeks following temozolomide initiation. Clinical and laboratory features, therapeutic response to exogenous desmopressin, and clinical course have been summarized.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by CMSR (center for medical study and research) foundation Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This article does not contain any studies with human subjects performed by any of the authors.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in tables and diagrams.